Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 10/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633078 | 1.00 | HTR1A (0.56) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL20970971 | 0.95 | HTR2A (0.52) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL29633123 | 0.95 | HTR2A (0.52) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL4212211 | 0.94 | HTR1A (0.63) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL29400822 | 0.94 | HTR1A (0.63) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| Fumaric Acid SCHEMBL30366691 | 0.94 | HTR1A (0.50) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL27084985 | 0.90 | HTR2A (0.57) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL27084739 | 0.90 | HTR2A (0.57) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL27084894 | 0.89 | HTR1A (0.54) | HTR1AHTR2AHTR6HTR2CHTR2B | |
| SCHEMBL31086232 | 0.89 | HTR2A (0.56) | HTR1AHTR2AHTR6HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| EP-4415710-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | Caamtech, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2023064840-A1 | CRYSTALLINE TRYPTAMINE COMPOUNDS | CAAMTECH, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12497361-B2 | Crystalline tryptamine compounds | CAAMTECH, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220054402-A1 | COMPOSITIONS AND METHODS FOR EXTRACTING, STABILIZING, AND MANUFACTURING STABLE DOSAGE FORMS OF PSILOCIN, PSYCHEDELIC DRUGS, ENTHEOGENS, AND MEDICINAL MUSHROOMS AS NANO-DIMENSIONAL DRUG DELIVERY STRUCTURES | KAUFMAN RICHARD C (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR1A 5/4885HTR2A 6/4885HTR6 10/4885 |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | HTR1A 4/4885HTR2A 1/4885HTR6 9/4885 |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1A 23/4885HTR2A 5/4885HTR6 13/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR1A 5/4885HTR2A 6/4885HTR6 3/4885 |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR1A 5/4885HTR2A 2/4885HTR6 10/4885 |
| US-12497361-B2 | Crystalline tryptamine compounds | TPH1, HTR5A, TPH2 | HTR1A 7/4885HTR2A 14/4885HTR6 11/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR1A 22/4885HTR2A 19/4885HTR6 16/4885 |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | HTR1A 38/4885HTR2A 13/4885HTR6 65/4885 |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR2, HCRTR1, HTR2A | HTR1A 9/4885HTR2A 3/4885HTR6 27/4885 |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR1A 5/4885HTR2A 2/4885HTR6 10/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR1A 2/4885HTR2A 14/4885HTR6 8/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR1A 2/4885HTR2A 16/4885HTR6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.